Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis. - Wikidata - wikimedia - TriplyDB

Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis.

Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis.

http://www.wikidata.org/entity/Q40427746

about

Dysfunctional adipose tissue and low-grade inflammation in the management of the metabolic syndrome: current practices and future advances Long-term drug survival and predictor analysis of the whole psoriatic patient population on biological therapy in Hungary.Evaluation of adherence predictors for the treatment of moderate to severe psoriasis with biologics: the importance of physician-patient interaction and communication.The impact of age on psoriasis health care in Germany.Drug survival of biologic treatments in psoriasis: a systematic review.Adherence to biologics in patients with psoriasis.Drug survival rates and reasons for drug discontinuation in psoriasis.Proposal for long-term protocols after Psoriasis Area and Severity Index clear with initial biologic therapy: Happily ever after with or without biologics in psoriasis therapy.Psoriasis treatment with adalimumab in clinical practice: long-term experience in a center for biological therapy in the Czech Republic."Drug-Survival"-Raten und Gründe für den Abbruch von Systemtherapien bei Psoriasis.Es hört doch jeder nur, was er versteht.Drug survival of biologics in treating psoriasis: a meta-analysis of real-world evidence

P2860

Q28070056-80F6008F-CC0F-4A2C-B9A6-DAD47E5C4511 Q38633601-BDE3DCCA-EA42-487C-B6D7-E6D3B9A865A9 Q38950074-5E121644-517F-4DAF-AA8E-7F1AB03FF904 Q39024781-3E728642-FC8D-42C5-B105-A3ACA0C1ECF5 Q46118586-97759E06-74CC-4583-82EF-D70FB5C1C922 Q47560483-3660D89A-3074-43DE-8714-B678169D9215 Q47624590-EAABAE39-91C4-491C-B7CD-F927A3FC2DB7 Q48263335-97CF9833-2F48-4AD8-828D-8ADF5E00A175 Q48298598-83623ABE-99D2-43A2-99E4-043E67B87D65 Q52844749-83BD0A92-EBC2-4B35-A341-8E31F8DA8F03 Q53740662-87E223B8-C9BB-4BBF-B509-B185262A2B81 Q58099097-DA0FE640-B1D3-4524-ACCB-9B935D090810

P2860

Comorbidity as a predictor for drug survival of biologic therapy in patients with psoriasis.

http://www.wikidata.org/entity/Q40427746

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Comorbidity as a predictor for ...... py in patients with psoriasis.

@en

type

label

Comorbidity as a predictor for ...... py in patients with psoriasis.

@en

prefLabel

Comorbidity as a predictor for ...... py in patients with psoriasis.

@en

P1433

Q40427746-1EE15797-6312-45B8-A910-006C434A8798

P1476

Q40427746-996FFC35-2F04-46FE-9E4D-4446900170F3

P2093

Q40427746-294593B6-BC20-4639-BE14-DBE4FBF60CDC

Q40427746-2968CF63-9132-4524-B3DA-FB9E8B304C68

Q40427746-5BE43A49-3EFB-4890-96FB-C5AA63795B1E

P2860

Q40427746-01A23FD4-587A-4CAE-BE01-03AF458D0B5A

Q40427746-0B07E546-42E4-4386-BBFC-8F09B0CF1A33

Q40427746-237A83AB-54F5-43A2-9F11-862EBB08076B

Q40427746-45B1413B-16D4-4283-BB5C-D1B92F13A9AE

Q40427746-4A899A14-7ABB-4B09-B2F1-8A1DBFDE3387

Q40427746-62A6C318-89AC-44AF-837E-B8E4B64120A1

Q40427746-659D49AE-C3AB-45A0-BFD8-316A98DA90C6

Q40427746-6B4A6FED-FEF4-4D26-B201-B4CD86A0B6B6

Q40427746-73A91AD4-F3A0-464E-9725-ABB72C49D445

Q40427746-79AFA115-4375-4523-8DFD-A139D4337EED

P304

Q40427746-A5CDA1E7-1A04-4B4F-9452-E4F99E427BB2

P31

Q40427746-63B78CB1-9000-4683-A06A-C05A0AC4C9E3

P356

Q40427746-2B3D6C38-F8D0-4535-BB8E-46B68B0AA239

P433

Q40427746-9EC0F8EA-8D21-4A20-9C71-C96118E8A1D0

P478

Q40427746-7AE9A80E-7C26-4D6B-A084-E623A2EAFC96

P577

Q40427746-5C0F1E10-ABAB-4F63-A239-168232BC7A8A

P698

Q40427746-526B33F8-EB94-45F9-B0D4-CF45894E1088

P356

P1433

International Journal of Dermatology

P1476

Comorbidity as a predictor for ...... py in patients with psoriasis.

@en

P2093

Arnd Jacobi

http://www.w3.org/2001/XMLSchema#string

Matthias Augustin

http://www.w3.org/2001/XMLSchema#string

Stephan J Rustenbach

http://www.w3.org/2001/XMLSchema#string

P2860

Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

Co-morbidity and age-related prevalence of psoriasis: Analysis of health insurance data in Germany.

Diet and weight loss as a treatment for psoriasis.

Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?

Psoriasis and cardiovascular risk: strength in numbers, part II.

Guidelines of care for the management of psoriasis and psoriatic arthritis: section 6. Guidelines of care for the treatment of psoriasis and psoriatic arthritis: case-based presentations and evidence-based conclusions.

Effect of tumour necrosis factor blockers on radiographic progression of psoriatic arthritis: a systematic review and meta-analysis of randomised controlled trials.

Prevalence and clinical features of psoriatic arthritis and joint complaints in 2009 patients with psoriasis: results of a German national survey.

Survival rate of antitumour necrosis factor-α treatments for psoriasis in routine dermatological practice: a multicentre observational study.

Progressive multifocal leukoencephalopathy associated with efalizumab use in psoriasis patients.

P304

296-302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/IJD.12879

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

55

http://www.w3.org/2001/XMLSchema#string

P577

2015-10-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26470689

http://www.w3.org/2001/XMLSchema#string